{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:30:59Z","timestamp":1793050259955,"version":"4.5.0"},"reference-count":230,"publisher":"Rockefeller University Press","issue":"11","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:p>Dysregulated signaling from TNF and TNFR proteins is implicated in several immune-mediated inflammatory diseases (IMIDs). This review centers around seven IMIDs (rheumatoid arthritis, systemic lupus erythematosus, Crohn\u2019s disease, ulcerative colitis, psoriasis, atopic dermatitis, and asthma) with substantial unmet medical needs and sheds light on the signaling mechanisms, disease relevance, and evolving drug development activities for five TNF\/TNFR signaling axes that garner substantial drug development interest in these focus conditions. The review also explores the current landscape of therapeutics, emphasizing the limitations of the approved biologics, and the opportunities presented by small-molecule inhibitors and combination antagonists of TNF\/TNFR signaling.<\/jats:p>","DOI":"10.1084\/jem.20240806","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T02:20:53Z","timestamp":1724725253000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":70,"title":["Targeting TNF\/TNFR superfamilies in immune-mediated inflammatory diseases"],"prefix":"10.1084","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8204-088X","authenticated-orcid":true,"given":"Praveen Krishna","family":"Veerasubramanian","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xdqrp08","id-type":"ROR","asserted-by":"publisher"}],"name":"Inflammation and Immunology Research Unit, Pfizer, Inc. 1 , Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-8731","authenticated-orcid":true,"given":"Thomas A.","family":"Wynn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xdqrp08","id-type":"ROR","asserted-by":"publisher"}],"name":"Inflammation and Immunology Research Unit, Pfizer, Inc. 1 , Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6894-3931","authenticated-orcid":true,"given":"Jie","family":"Quan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xdqrp08","id-type":"ROR","asserted-by":"publisher"}],"name":"Inflammation and Immunology Research Unit, Pfizer, Inc. 1 , Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4381-3860","authenticated-orcid":true,"given":"Fridrik J.","family":"Karlsson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xdqrp08","id-type":"ROR","asserted-by":"publisher"}],"name":"Inflammation and Immunology Research Unit, Pfizer, Inc. 1 , Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"2024091913434023700_bib1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1681\/ASN.2007060706","article-title":"TL1A both promotes and protects from renal inflammation and injury","volume":"19","author":"Al-Lamki","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"2024091913434023700_bib2","article-title":"Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy. Alpine Immune Sciences Inc. (Press release)","author":"Alpine Immune Sciences","year":"2024"},{"key":"2024091913434023700_bib3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000573","article-title":"New pathways in immune stimulation: Targeting OX40","volume":"5","author":"Alves Costa Silva","year":"2020","journal-title":"ESMO Open"},{"key":"2024091913434023700_bib4","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.4049\/jimmunol.144.7.2582","article-title":"Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma","volume":"144","author":"Andrews","year":"1990","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molmed.2017.11.002","article-title":"Checkpoints in TNF-induced cell death: Implications in inflammation and cancer","volume":"24","author":"Annibaldi","year":"2018","journal-title":"Trends Mol. Med."},{"key":"2024091913434023700_bib6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"2024091913434023700_bib7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"2024091913434023700_bib8","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.4049\/jimmunol.171.9.4868","article-title":"Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease","volume":"171","author":"Bamias","year":"2003","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.clim.2010.07.001","article-title":"High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis","volume":"137","author":"Bamias","year":"2010","journal-title":"Clin. Immunol."},{"key":"2024091913434023700_bib10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.dld.2011.09.002","article-title":"Differential expression of the TL1A\/DcR3 system of TNF\/TNFR-like proteins in large vs. small intestinal Crohn\u2019s disease","volume":"44","author":"Bamias","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"2024091913434023700_bib11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1084\/jem.192.10.1453","article-title":"BAFF mediates survival of peripheral immature B lymphocytes","volume":"192","author":"Batten","year":"2000","journal-title":"J. Exp. Med."},{"key":"2024091913434023700_bib12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"2024091913434023700_bib13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/19420862.2019.1624463","article-title":"Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease","volume":"11","author":"Benschop","year":"2019","journal-title":"MAbs"},{"key":"2024091913434023700_bib14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4419","article-title":"Additive efficacy of a bispecific anti-TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis","volume":"15","author":"Biesemann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"2024091913434023700_bib15","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1021\/acs.jmedchem.6b01836","article-title":"Structural basis of small-molecule aggregate induced inhibition of a protein\u2013protein interaction","volume":"60","author":"Blevitt","year":"2017","journal-title":"J. Med. Chem."},{"key":"2024091913434023700_bib16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/molecules23051153","article-title":"Design, synthesis, and evaluation of novel immunomodulatory small molecules targeting the CD40\u2212CD154 costimulatory protein-protein interaction","volume":"23","author":"Bojadzic","year":"2018","journal-title":"Molecules"},{"key":"2024091913434023700_bib17","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1182\/blood-2007-09-110874","article-title":"TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts","volume":"111","author":"Bossen","year":"2008","journal-title":"Blood"},{"key":"2024091913434023700_bib18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib19","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1126\/science.1072615","article-title":"A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory","volume":"297","author":"Bourgeois","year":"2002","journal-title":"Science"},{"key":"2024091913434023700_bib20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: A randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"2024091913434023700_bib21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib22","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1038\/s41467-023-41180-2","article-title":"European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation","volume":"14","author":"Budu-Aggrey","year":"2023","journal-title":"Nat. Commun."},{"key":"2024091913434023700_bib23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.42415","article-title":"Efficacy and safety of ABBV-3373, a novel anti-tumor necrosis factor glucocorticoid receptor modulator antibody-drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: A randomized, double-blind, active-controlled proof-of-concept phase IIa trial","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"2024091913434023700_bib24","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024091913434023700_bib25","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib26","doi-asserted-by":"publisher","first-page":"7325","DOI":"10.4049\/jimmunol.178.11.7325","article-title":"Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis","volume":"178","author":"Cassatella","year":"2007","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20032000","article-title":"TACI and BAFF-R mediate isotype switching in B cells","volume":"201","author":"Castigli","year":"2005","journal-title":"J. Exp. Med."},{"key":"2024091913434023700_bib28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2022.09.001","article-title":"Genetic architecture of asthma in African American patients","volume":"151","author":"Chang","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"2024091913434023700_bib29","doi-asserted-by":"publisher","first-page":"14575","DOI":"10.1016\/S0021-9258(17)36662-0","article-title":"Tumor necrosis factor and lymphotoxin. Qualitative and quantitative differences in the mediation of early and late cellular response","volume":"269","author":"Chaturvedi","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2024091913434023700_bib30","doi-asserted-by":"publisher","first-page":"8906","DOI":"10.1021\/acs.jmedchem.7b01154","article-title":"Small-molecule inhibitors of the CD40-CD40L costimulatory protein-protein interaction","volume":"60","author":"Chen","year":"2017","journal-title":"J. Med. Chem."},{"key":"2024091913434023700_bib31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2024091913434023700_bib32","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1038\/s41598-018-23277-7","article-title":"Preclinical development of a novel, orally-administered anti-tumour necrosis factor domain antibody for the treatment of inflammatory bowel disease","volume":"8","author":"Crowe","year":"2018","journal-title":"Sci. Rep."},{"key":"2024091913434023700_bib33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/03639045.2018.1542708","article-title":"Oral delivery of the anti-tumor necrosis factor \u03b1 domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys","volume":"45","author":"Crowe","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"2024091913434023700_bib34","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1182\/blood-2023-180055","article-title":"Ianalumab, a novel anti-B-cell activating factor (BAFF) receptor (BAFF-R) monoclonal antibody (mAb) in development for immune Thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), has demonstrated a favorable safety profile in Sj\u00f6gren\u2019s syndrome (SjS), systemic lupus erythematosus (SLE) and chronic lymphocytic leukemia (CLL)","volume":"142","author":"Cuker","year":"2023","journal-title":"Blood"},{"key":"2024091913434023700_bib35","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: A phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"2024091913434023700_bib36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/rheumatology\/kel229","article-title":"Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis","volume":"46","author":"Daoussis","year":"2007","journal-title":"Rheumatology"},{"key":"2024091913434023700_bib37","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/gast.2000.16485","article-title":"Chronic murine colitis is dependent on the CD154\/CD40 pathway and can be attenuated by anti-CD154 administration","volume":"119","author":"De Jong","year":"2000","journal-title":"Gastroenterology"},{"key":"2024091913434023700_bib38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ng.3760","article-title":"Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease","volume":"49","author":"de Lange","year":"2017","journal-title":"Nat. Genet."},{"key":"2024091913434023700_bib39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fimmu.2019.00003","article-title":"Polarization of rheumatoid macrophages by TNF targeting through an IL-10\/STAT3 mechanism","volume":"10","author":"Degbo\u00e9","year":"2019","journal-title":"Front. Immunol."},{"key":"2024091913434023700_bib40","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/ibd\/izab029","article-title":"Human intestinal macrophages are involved in the pathology of both ulcerative colitis and crohn disease","volume":"27","author":"Dharmasiri","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"2024091913434023700_bib41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1021\/acs.jmedchem.0c01280","article-title":"Development of orally efficacious allosteric inhibitors of TNF\u03b1 via fragment-based drug design","volume":"64","author":"Dietrich","year":"2021","journal-title":"J. Med. Chem."},{"key":"2024091913434023700_bib42","doi-asserted-by":"publisher","first-page":"i025","DOI":"10.1093\/ecco-jcc\/jjab232.022","article-title":"OP23 the efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12","volume":"16","author":"Dignass","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"2024091913434023700_bib43","first-page":"956","article-title":"Pos0540 reduction of b cell subsets, autoantibodies and disease-relevant pathways in ianalumab treated patients with systemic lupus erythematosus: Findings from a phase 2 clinical trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"2024091913434023700_bib44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/0976-500X.85930","article-title":"Belimumab: First targeted biological treatment for systemic lupus erythematosus","volume":"2","author":"Dubey","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"key":"2024091913434023700_bib45","doi-asserted-by":"publisher","first-page":"47ra63","DOI":"10.1126\/scitranslmed.3001001","article-title":"Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"2","author":"Duffau","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"2024091913434023700_bib46","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.7689748","article-title":"Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40","volume":"261","author":"Durie","year":"1993","journal-title":"Science"},{"key":"2024091913434023700_bib47","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/ecco-jcc\/jjad151","article-title":"Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn\u2019s disease patients: A prospective open-label study","volume":"17","author":"D\u2019Haens","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"2024091913434023700_bib48","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: Danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"2024091913434023700_bib49","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat. Genet."},{"key":"2024091913434023700_bib50","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib51","doi-asserted-by":"publisher","first-page":"adv00099","DOI":"10.2340\/00015555-3452","article-title":"The OX40 Axis is associated with both systemic and local involvement in atopic dermatitis","volume":"100","author":"Elsner","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"2024091913434023700_bib52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am. J. Transpl."},{"key":"2024091913434023700_bib53","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1111\/febs.12419","article-title":"Lymphotoxin \u03b1 induces apoptosis, necroptosis and inflammatory signals with the same potency as tumour necrosis factor","volume":"280","author":"Etemadi","year":"2013","journal-title":"FEBS J."},{"key":"2024091913434023700_bib54","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"2024091913434023700_bib55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today"},{"key":"2024091913434023700_bib56","article-title":"Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates. Fate Therapeutics Inc. (Press release)","author":"Fate Therapeutics Inc","year":"2023"},{"key":"2024091913434023700_bib57","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: Drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"2024091913434023700_bib58","doi-asserted-by":"publisher","first-page":"i162","DOI":"10.1093\/ecco-jcc\/jjac190.0127","article-title":"DOP87 the anti-TL1A antibody PRA023 demonstrated proof-of-concept in Crohn\u2019s disease: Phase 2a APOLLO-CD study results","volume":"17","author":"Feagan","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"2024091913434023700_bib59","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2024091913434023700_bib60","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ajhg.2019.02.022","article-title":"Genetic architectures of childhood- and adult-onset asthma are partly distinct","volume":"104","author":"Ferreira","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"2024091913434023700_bib61","first-page":"S563","article-title":"A novel individualized treatment approach in open-label extension study of ozoralizumab (ATN-103) in subjects with rheumatoid arthritis on a background of methotrexate","volume-title":"Arthritis and Rheumatism","author":"Fleischmann","year":"2012"},{"key":"2024091913434023700_bib62","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ng.717","article-title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci","volume":"42","author":"Franke","year":"2010","journal-title":"Nat. Genet."},{"key":"2024091913434023700_bib63","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"2024091913434023700_bib64","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2011.05.016","article-title":"Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets","volume":"128","author":"Fujita","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"2024091913434023700_bib65","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1210\/endo.143.3.8701","article-title":"TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL","volume":"143","author":"Fuller","year":"2002","journal-title":"Endocrinology"},{"key":"2024091913434023700_bib66","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib67","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2024091913434023700_bib68","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"key":"2024091913434023700_bib69","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.3390\/jcm10122578","article-title":"OX40L-OX40 signaling in atopic dermatitis","volume":"10","author":"Furue","year":"2021","journal-title":"J. Clin. Med."},{"key":"2024091913434023700_bib70","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.4049\/jimmunol.174.7.3891","article-title":"Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory","volume":"174","author":"Gaspal","year":"2005","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib71","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.4049\/jimmunol.180.5.2824","article-title":"Critical synergy of CD30 and OX40 signals in CD4 T cell homeostasis and Th1 immunity to Salmonella","volume":"180","author":"Gaspal","year":"2008","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib72","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1084\/jem.20101484","article-title":"Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice","volume":"208","author":"Gaspal","year":"2011","journal-title":"J. Exp. Med."},{"key":"2024091913434023700_bib73","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: A randomized, double-blind study","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"2024091913434023700_bib74","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: A proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"2024091913434023700_bib75","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jaut.2006.02.002","article-title":"Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases","volume":"26","author":"Goules","year":"2006","journal-title":"J. Autoimmun."},{"key":"2024091913434023700_bib76","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.jaci.2020.10.037","article-title":"Combination blockade of OX40L and CD30L inhibits allergen-driven memory TH2 cell reactivity and lung inflammation","volume":"147","author":"Gracias","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"2024091913434023700_bib77","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1172\/JCI200319301","article-title":"Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions","volume":"112","author":"Grammer","year":"2003","journal-title":"J. Clin. Invest."},{"key":"2024091913434023700_bib78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41927-021-00192-5","article-title":"Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential","volume":"5","author":"Grayling","year":"2021","journal-title":"BMC Rheumatol."},{"key":"2024091913434023700_bib79","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125306","article-title":"Lymphocyte mass cytometry identifies a CD3-CD4+ cell subset with a potential role in psoriasis","volume":"4","author":"Guo","year":"2019","journal-title":"JCI Insight"},{"key":"2024091913434023700_bib80","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi8823","article-title":"TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy","volume":"6","author":"Gupta","year":"2021","journal-title":"Sci. Immunol."},{"key":"2024091913434023700_bib81","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: A multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"key":"2024091913434023700_bib82","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/s41467-020-15649-3","article-title":"Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma","volume":"11","author":"Han","year":"2020","journal-title":"Nat. Commun."},{"key":"2024091913434023700_bib83","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2024091913434023700_bib84","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.4049\/jimmunol.181.3.2211","article-title":"Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator\/B cell-activating factor\/TNF ligand superfamily-13B","volume":"181","author":"Harigai","year":"2008","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib85","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ibd\/izab193","article-title":"Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis","volume":"28","author":"Hassan-Zahraee","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"2024091913434023700_bib86","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1126\/science.1116304","article-title":"Small-molecule inhibition of TNF-alpha","volume":"310","author":"He","year":"2005","journal-title":"Science"},{"key":"2024091913434023700_bib87","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3389\/fimmu.2018.01556","article-title":"The p38 MAPK inhibitor SB203580 abrogates tumor necrosis factor-induced proliferative expansion of mouse CD4+Foxp3+ regulatory T cells","volume":"9","author":"He","year":"2018","journal-title":"Front. Immunol."},{"key":"2024091913434023700_bib88","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1084\/jem.20100857","article-title":"A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling","volume":"207","author":"Hildebrand","year":"2010","journal-title":"J. Exp. Med."},{"key":"2024091913434023700_bib89","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41588-022-01213-w","article-title":"Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis","volume":"54","author":"Ishigaki","year":"2022","journal-title":"Nat. Genet."},{"key":"2024091913434023700_bib90","doi-asserted-by":"publisher","first-page":"18189","DOI":"10.1038\/s41598-020-75168-5","article-title":"Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo","volume":"10","author":"Jacob","year":"2020","journal-title":"Sci. Rep."},{"key":"2024091913434023700_bib91","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122167","article-title":"OX40L\/OX40 axis impairs follicular and natural Treg function in human SLE","volume":"3","author":"Jacquemin","year":"2018","journal-title":"JCI Insight"},{"key":"2024091913434023700_bib92","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abi8713","article-title":"An orally active, small-molecule TNF inhibitor that disrupts the homotrimerization interface improves inflammatory arthritis in mice","volume":"15","author":"Javaid","year":"2022","journal-title":"Sci. Signal."},{"key":"2024091913434023700_bib93","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.193.3.387","article-title":"Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40","volume":"193","author":"Jember","year":"2001","journal-title":"J. Exp. Med."},{"key":"2024091913434023700_bib94","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.283.5401.543","article-title":"Prevention of constitutive TNF receptor 1 signaling by silencer of death domains","volume":"283","author":"Jiang","year":"1999","journal-title":"Science"},{"key":"2024091913434023700_bib95","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41586-024-07469-y","article-title":"A body-brain circuit that regulates body inflammatory responses","volume":"630","author":"Jin","year":"2024","journal-title":"Nature"},{"key":"2024091913434023700_bib96","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1093\/hmg\/ddz175","article-title":"Genome-wide association analysis of 350\u2009000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema","volume":"28","author":"Johansson","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"2024091913434023700_bib97","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","article-title":"Defining response to TNF-inhibitors in rheumatoid arthritis: The negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders","volume":"38","author":"Johnson","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"2024091913434023700_bib98","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"2024091913434023700_bib99","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1093\/hmg\/ddac101","article-title":"Identification of shared loci associated with both Crohn\u2019s disease and leprosy in East Asians","volume":"31","author":"Jung","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"2024091913434023700_bib100","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"2024091913434023700_bib101","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat. Med."},{"key":"2024091913434023700_bib102","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib103","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {\u03b1} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"2024091913434023700_bib104","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ajhg.2018.11.008","article-title":"Leveraging polygenic functional enrichment to improve GWAS power","volume":"104","author":"Kichaev","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"2024091913434023700_bib105","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.4049\/jimmunol.176.2.1026","article-title":"TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo","volume":"176","author":"Kim","year":"2006","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib106","article-title":"Kiniksa Pharmaceuticals provides corporate update. kiniksa pharmaceuticals corp. (Press release)","author":"Kiniksa Pharmaceuticals","year":"2024"},{"key":"2024091913434023700_bib107","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003317","article-title":"The MIDORA trial: A phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis","volume":"9","author":"Kivitz","year":"2023","journal-title":"RMD Open"},{"key":"2024091913434023700_bib108","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"2024091913434023700_bib109","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.44245","article-title":"The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets","volume":"8","author":"Koike","year":"2019","journal-title":"Elife"},{"key":"2024091913434023700_bib110","doi-asserted-by":"publisher","first-page":"8284","DOI":"10.1073\/pnas.1605635113","article-title":"Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis","volume":"113","author":"Koopman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024091913434023700_bib111","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"2024091913434023700_bib112","doi-asserted-by":"publisher","first-page":"782788","DOI":"10.3389\/fimmu.2021.782788","article-title":"Immune complex formation is associated with loss of tolerance and an antibody response to both drug and target","volume":"12","author":"Kroenke","year":"2021","journal-title":"Front. Immunol."},{"key":"2024091913434023700_bib113","doi-asserted-by":"publisher","first-page":"1185300","DOI":"10.3389\/fmed.2023.1185300","article-title":"Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea","volume":"10","author":"Kwon","year":"2023","journal-title":"Front. Med."},{"key":"2024091913434023700_bib114","doi-asserted-by":"publisher","first-page":"16021","DOI":"10.1038\/ncomms16021","article-title":"Transancestral mapping and genetic load in systemic lupus erythematosus","volume":"8","author":"Langefeld","year":"2017","journal-title":"Nat. Commun."},{"key":"2024091913434023700_bib115","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1160\/TH04-12-0774","article-title":"The role of CD40 in CD40L- and antibody-mediated platelet activation","volume":"93","author":"Langer","year":"2005","journal-title":"Thromb. Haemost."},{"key":"2024091913434023700_bib116","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"2024091913434023700_bib117","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-eurolupus.176","article-title":"P132 Design of an adaptive, phase 2, placebo-controlled, dose-ranging study to assess the efficacy and safety of AMG 570 in subjects with active SLE and inadequate response to standard of care therapy","volume":"7","author":"Lei","year":"2020","journal-title":"Lupus Sci. Med."},{"key":"2024091913434023700_bib118","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.3933","article-title":"Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases","volume":"21","author":"Li","year":"2015","journal-title":"Nat. Med."},{"key":"2024091913434023700_bib119","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.prp.2017.11.017","article-title":"TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice","volume":"214","author":"Li","year":"2018","journal-title":"Pathol. Res. Pract."},{"key":"2024091913434023700_bib120","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"2024091913434023700_bib121","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat. Immunol."},{"key":"2024091913434023700_bib122","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/08916930109001958","article-title":"Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment","volume":"34","author":"Liu","year":"2001","journal-title":"Autoimmunity"},{"key":"2024091913434023700_bib123","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat. Genet."},{"key":"2024091913434023700_bib124","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/08923979209005404","article-title":"Serum tumor necrosis factor activity in inflammatory bowel disease","volume":"14","author":"Maeda","year":"1992","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"2024091913434023700_bib125","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/JIR.S67751","article-title":"Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor","volume":"7","author":"Manetta","year":"2014","journal-title":"J. Inflamm. Res."},{"key":"2024091913434023700_bib126","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1073\/pnas.94.15.8093","article-title":"Characterization of tumor necrosis factor-deficient mice","volume":"94","author":"Marino","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2024091913434023700_bib127","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13075-020-02372-z","article-title":"Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients","volume":"23","author":"Marken","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"2024091913434023700_bib128","doi-asserted-by":"publisher","first-page":"174285","DOI":"10.1016\/j.ejphar.2021.174285","article-title":"New contributions to the drug profile of TNF\u03b1 inhibitor SPD304: Affinity, selectivity and ADMET considerations","volume":"907","author":"Mascret","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"2024091913434023700_bib129","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41467-020-20828-3","article-title":"Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF","volume":"12","author":"McMillan","year":"2021","journal-title":"Nat. Commun."},{"key":"2024091913434023700_bib130","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"2024091913434023700_bib131","article-title":"Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. Merck & Co. Inc. (Press release)","author":"Merck & Co. Inc","year":"2023"},{"key":"2024091913434023700_bib132","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"2024091913434023700_bib133","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4049\/jimmunol.178.2.671","article-title":"A costimulatory function for T cell CD40","volume":"178","author":"Munroe","year":"2007","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib134","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/1346-8138.15664","article-title":"Basics and recent advances in the pathophysiology of atopic dermatitis","volume":"48","author":"Nakahara","year":"2021","journal-title":"J. Dermatol."},{"key":"2024091913434023700_bib135","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12964-020-00564-3","article-title":"The TNF\/TNFR2 signaling pathway is a key regulatory factor in endothelial progenitor cell immunosuppressive effect","volume":"18","author":"Naserian","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"2024091913434023700_bib136","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2024091913434023700_bib137","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/978-0-387-89520-8_12","article-title":"Targeting CD30\/CD30L in oncology and autoimmune and inflammatory diseases","volume-title":"Therapeutic Targets of the TNF Superfamily","author":"Oflazoglu","year":"2009"},{"key":"2024091913434023700_bib138","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4049\/jimmunol.174.2.864","article-title":"Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines","volume":"174","author":"Ohata","year":"2005","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib139","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/j.gastro.2011.05.048","article-title":"HLA-Cw*1202-B*5201-DRB1*1502 haplotype increases risk for ulcerative colitis but reduces risk for Crohn\u2019s disease","volume":"141","author":"Okada","year":"2011","journal-title":"Gastroenterology"},{"key":"2024091913434023700_bib140","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"key":"2024091913434023700_bib141","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41467-019-14144-8","article-title":"Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis","volume":"11","author":"Olafsdottir","year":"2020","journal-title":"Nat. Commun."},{"key":"2024091913434023700_bib142","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1038\/s41467-019-13616-1","article-title":"Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer","volume":"10","author":"O\u2019Connell","year":"2019","journal-title":"Nat. Commun."},{"key":"2024091913434023700_bib143","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.4049\/jimmunol.172.11.7002","article-title":"TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells","volume":"172","author":"Papadakis","year":"2004","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib144","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"2024091913434023700_bib145","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/jdv.14313","article-title":"Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis","volume":"31","author":"Papp","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2024091913434023700_bib146","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"2024091913434023700_bib147","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1084\/jem.184.4.1397","article-title":"Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response","volume":"184","author":"Pasparakis","year":"1996","journal-title":"J. Exp. Med."},{"key":"2024091913434023700_bib148","doi-asserted-by":"publisher","first-page":"103948","DOI":"10.1016\/j.drudis.2024.103948","article-title":"Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development","volume":"29","author":"Peeva","year":"2024","journal-title":"Drug Discov. Today"},{"key":"2024091913434023700_bib149","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib150","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S2213-2600(19)30055-4","article-title":"Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: Genome-wide and transcriptome-wide studies","volume":"7","author":"Pividori","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"2024091913434023700_bib151","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clim.2004.02.007","article-title":"Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation","volume":"112","author":"Prehn","year":"2004","journal-title":"Clin. Immunol."},{"key":"2024091913434023700_bib152","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"2024091913434023700_bib153","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"2024091913434023700_bib154","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.jacig.2023.100195","article-title":"Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis","volume":"3","author":"Rewerska","year":"2023","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"2024091913434023700_bib155","first-page":"145","article-title":"The tumour necrosis factor family of receptors\/ligands in the serum of patients with rheumatoid arthritis","volume":"9","author":"Robak","year":"1998","journal-title":"Eur. Cytokine Netw."},{"key":"2024091913434023700_bib156","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","article-title":"Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice","volume":"185","author":"Robles-Carrillo","year":"2010","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib157","article-title":"Roivant announces statistically significant and clinically meaningful results from the induction period of TUSCANY-2, a large global phase 2b study of subcutaneous RVT-3101 for the treatment of ulcerative colitis in both the overall and the biomarker positive patient populations. Roivant Sciences Ltd. (Press release)","author":"Roivant Sciences Ltd","year":"2023"},{"key":"2024091913434023700_bib158","article-title":"Roivant reports chronic period data for RVT-3101 from the TUSCANY-2 phase 2b study in ulcerative colitis, demonstrating improved efficacy from the induction to chronic period. Roivant Sciences Ltd. (Press release)","author":"Roivant Sciences Ltd","year":"2023"},{"key":"2024091913434023700_bib159","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2024091913434023700_bib160","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","article-title":"A cross-population atlas of genetic associations for 220 human phenotypes","volume":"53","author":"Sakaue","year":"2021","journal-title":"Nat. Genet."},{"key":"2024091913434023700_bib161","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2024091913434023700_bib162","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"2024091913434023700_bib163","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: Induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"2024091913434023700_bib164","doi-asserted-by":"publisher","first-page":"i56","DOI":"10.1093\/ecco-jcc\/jjac190.0040","article-title":"OP40 PRA023 demonstrated efficacy and favorable safety as induction therapy for moderately to severely active UC: Phase 2 ARTEMIS-UC study results","volume":"17","author":"Sands","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"2024091913434023700_bib165","article-title":"Press release: New phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis","author":"Sanofi","year":"2024"},{"key":"2024091913434023700_bib166","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab versus methotrexate versus placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"2024091913434023700_bib167","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.bbrc.2015.06.153","article-title":"p62 regulates CD40-mediated NF\u03baB activation in macrophages through interaction with TRAF6","volume":"464","author":"Seibold","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2024091913434023700_bib168","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1172\/JCI33559","article-title":"In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation","volume":"117","author":"Seshasayee","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2024091913434023700_bib170","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.anai.2023.08.275","article-title":"Safety and pharmacokinetics of IMG-007, AN OX40 monoclonal antibody, in healthy adults","volume":"131","author":"Shen","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"2024091913434023700_bib171","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3389\/fimmu.2018.01849","article-title":"Tumor necrosis factor receptor-associated factor regulation of nuclear factor \u03baB and mitogen-activated protein kinase pathways","volume":"9","author":"Shi","year":"2018","journal-title":"Front. Immunol."},{"key":"2024091913434023700_bib172","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1756283X09336364","article-title":"Predicting response to Anti-TNF Agents for the treatment of crohn\u2019s disease","volume":"2","author":"Siegel","year":"2009","journal-title":"Therap. Adv. Gastroenterol."},{"key":"2024091913434023700_bib173","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1021\/cb2000346","article-title":"Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism","volume":"6","author":"Silvian","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"2024091913434023700_bib174","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13911","article-title":"A 12-month pilot study outcomes of vagus nerve stimulation in Crohn\u2019s disease","volume":"32","author":"Sinniger","year":"2020","journal-title":"Neurogastroenterol. Motil."},{"key":"2024091913434023700_bib175","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","article-title":"Rheumatoid arthritis therapy reappraisal: Strategies, opportunities and challenges","volume":"11","author":"Smolen","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"2024091913434023700_bib176","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"2024091913434023700_bib177","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-981-32-9717-3_3","article-title":"The TNF-TNFR family of Co-signal molecules","volume":"1189","author":"So","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"2024091913434023700_bib178","doi-asserted-by":"publisher","first-page":"D977","DOI":"10.1093\/nar\/gkac1010","article-title":"The NHGRI-EBI GWAS catalog: Knowledgebase and deposition resource","volume":"51","author":"Sollis","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"2024091913434023700_bib179","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib180","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the cytokine BAFF and autoimmunity risk","volume":"376","author":"Steri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2024091913434023700_bib181","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib182","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib183","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3899\/jrheum.120886","article-title":"Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"40","author":"Stohl","year":"2013","journal-title":"J. Rheumatol."},{"key":"2024091913434023700_bib184","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1084\/jem.183.2.693","article-title":"Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion","volume":"183","author":"Stuber","year":"1996","journal-title":"J. Exp. Med."},{"key":"2024091913434023700_bib185","doi-asserted-by":"publisher","first-page":"8146","DOI":"10.1021\/acs.jmedchem.0c00377","article-title":"Discovery of an orally active small-molecule tumor necrosis factor-\u03b1 inhibitor","volume":"63","author":"Sun","year":"2020","journal-title":"J. Med. Chem."},{"key":"2024091913434023700_bib186","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ejphar.2013.08.017","article-title":"Histamine inhibits high mobility group box 1-induced adhesion molecule expression on human monocytes","volume":"718","author":"Takahashi","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"2024091913434023700_bib187","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1053\/j.gastro.2008.04.037","article-title":"TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation","volume":"135","author":"Takedatsu","year":"2008","journal-title":"Gastroenterology"},{"key":"2024091913434023700_bib188","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","article-title":"Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"2024091913434023700_bib189","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/art.42273","article-title":"Phase II\/III results of a trial of anti-tumor necrosis factor multivalent nanobody compound ozoralizumab in patients with rheumatoid arthritis","volume":"74","author":"Takeuchi","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"2024091913434023700_bib190","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/art.10860","article-title":"Local production of B lymphocyte stimulator protein and april in arthritic joints of patients with inflammatory arthritis","volume":"48","author":"Tan","year":"2003","journal-title":"Arthritis Rheum."},{"key":"2024091913434023700_bib191","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/mr\/roac126","article-title":"Efficacy and safety of anti-TNF multivalent nanobody\u00ae compound \u201cozoralizumab\u201d without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"2024091913434023700_bib192","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"2024091913434023700_bib193","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/mi.2010.70","article-title":"Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia","volume":"4","author":"Taraban","year":"2011","journal-title":"Mucosal Immunol."},{"key":"2024091913434023700_bib194","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3389\/fimmu.2017.01484","article-title":"CD40L expression allows CD8+ T cells to promote their own expansion and differentiation through dendritic cells","volume":"8","author":"Tay","year":"2017","journal-title":"Front. Immunol."},{"key":"2024091913434023700_bib195","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jaut.2018.05.002","article-title":"B-cell activating factor and related genetic variants in lupus related atherosclerosis","volume":"92","author":"Theodorou","year":"2018","journal-title":"J. Autoimmun."},{"key":"2024091913434023700_bib196","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1093\/rheumatology\/kev420","article-title":"Exploring BAFF: Its expression, receptors and contribution to the immunopathogenesis of Sj\u00f6gren\u2019s syndrome","volume":"55","author":"Thompson","year":"2016","journal-title":"Rheumatology"},{"key":"2024091913434023700_bib197","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3085","article-title":"Combined OX40L and mTOR blockade controls effector T cell activation while preserving T(reg) reconstitution after transplant","volume":"9","author":"Tkachev","year":"2017","journal-title":"Sci. Transl Med."},{"key":"2024091913434023700_bib198","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/08923973.2015.1130721","article-title":"Biologics beyond TNF-alpha inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders","volume":"38","author":"Tougaard","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"2024091913434023700_bib199","doi-asserted-by":"publisher","first-page":"15382","DOI":"10.1038\/ncomms15382","article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat. Commun."},{"key":"2024091913434023700_bib200","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: A road to inflammation","volume":"23","author":"van Loo","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"2024091913434023700_bib201","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.4049\/jimmunol.1202752","article-title":"Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function","volume":"191","author":"Voo","year":"2013","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib202","doi-asserted-by":"publisher","first-page":"1037983","DOI":"10.3389\/fphar.2022.1037983","article-title":"An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis","volume":"13","author":"Vugler","year":"2022","journal-title":"Front. Pharmacol."},{"key":"2024091913434023700_bib203","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2369-15-178","article-title":"TL1-A can engage death receptor-3 and activate NF-kappa B in endothelial cells","volume":"15","author":"Wang","year":"2014","journal-title":"BMC Nephrol."},{"key":"2024091913434023700_bib204","doi-asserted-by":"publisher","first-page":"12079","DOI":"10.1038\/s41598-018-30621-4","article-title":"TNFR2 ligation in human T regulatory cells enhances IL2-induced cell proliferation through the non-canonical NF-\u03baB pathway","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"key":"2024091913434023700_bib205","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201258","article-title":"A small molecule selected from a DNA-encoded library of natural products that binds to TNF-\u03b1 and attenuates inflammation in vivo","volume":"9","author":"Wang","year":"2022","journal-title":"Adv. Sci."},{"key":"2024091913434023700_bib206","first-page":"90","article-title":"OP0137 efficacy and safety of telitacicept, a novel blys\/april dual inhibitor, in patients with systemic lupus erythematosus: A phase 3, randomized, placebo-controlled 52-week study","volume":"82","author":"Wang","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"2024091913434023700_bib207","doi-asserted-by":"publisher","first-page":"ard-2024-225785","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: A phase 1 open-label clinical trial","volume":"30","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"2024091913434023700_bib208","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12016-015-8498-3","article-title":"OX40, OX40L and autoimmunity: A comprehensive review","volume":"50","author":"Webb","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2024091913434023700_bib209","doi-asserted-by":"publisher","first-page":"AB123","DOI":"10.1016\/j.jaad.2022.06.525","article-title":"34312 treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis","volume":"87","author":"Weidinger","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"2024091913434023700_bib210","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1016\/j.jid.2023.09.235","article-title":"227 efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a phase 2b trial (STREAM-AD)","volume":"143","author":"Weidinger","year":"2023","journal-title":"J. Invest. Dermatol."},{"key":"2024091913434023700_bib211","doi-asserted-by":"publisher","first-page":"ljac140.039","DOI":"10.1093\/bjd\/ljac140.039","article-title":"345 treatment with amlitelimab\u2014a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody\u2014reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis","volume":"188","author":"Weidinger","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"2024091913434023700_bib212","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.4049\/jimmunol.0901514","article-title":"The survival of memory CD4+ T cells within the gut lamina propria requires OX40 and CD30 signals","volume":"183","author":"Withers","year":"2009","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib213","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3858\/emm.2011.43.6.038","article-title":"Regulation of B cell activating factor (BAFF) receptor expression by NF-\u039aB signaling in rheumatoid arthritis B cells","volume":"43","author":"Woo","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"2024091913434023700_bib214","first-page":"4546","article-title":"Telitacicept, a human recombinant fusion protein targeting b lymphocyte stimulator (Blys) and a proliferation-inducing ligand (April), in systemic lupus erythematosus (Sle): Results of a phase 3 study","volume-title":"Arthritis & Rheumatology","author":"Wu","year":"2022"},{"key":"2024091913434023700_bib215","doi-asserted-by":"publisher","first-page":"15050","DOI":"10.1021\/acs.jmedchem.0c01732","article-title":"Biologic-like in vivo efficacy with small molecule inhibitors of TNF\u03b1 identified using scaffold hopping and structure-based drug design approaches","volume":"63","author":"Xiao","year":"2020","journal-title":"J. Med. Chem."},{"key":"2024091913434023700_bib216","doi-asserted-by":"publisher","first-page":"891328","DOI":"10.3389\/fimmu.2022.891328","article-title":"Role of TL1A in inflammatory autoimmune diseases: A Comprehensive review","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Immunol."},{"key":"2024091913434023700_bib217","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.gastro.2012.12.021","article-title":"A genome-wide association study identifies 2 susceptibility Loci for Crohn\u2019s disease in a Japanese population","volume":"144","author":"Yamazaki","year":"2013","journal-title":"Gastroenterology"},{"key":"2024091913434023700_bib218","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1007\/s10620-019-05580-z","article-title":"Effects and mechanism of constitutive TL1A expression on intestinal mucosal barrier in DSS-induced colitis","volume":"64","author":"Yang","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"2024091913434023700_bib219","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28570","article-title":"Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID-19 outcomes: Genome-wide cross trait analysis and bidirectional Mendelian randomization study","volume":"95","author":"Yao","year":"2023","journal-title":"J. Med. Virol."},{"key":"2024091913434023700_bib220","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2020-219209","article-title":"Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus","volume":"80","author":"Yin","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"2024091913434023700_bib221","article-title":"Novel BCMA-CD19 compound CAR-T (cCAR) targets B cells and plasma cells achieving immune reset and eliminates all autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients resulting in long-term, medication-free remission","volume-title":"ACR Convergence 2023","author":"Yuan","year":"2024"},{"key":"2024091913434023700_bib222","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J. Immunol."},{"key":"2024091913434023700_bib223","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/intimm\/dxh259","article-title":"BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors","volume":"17","author":"Zhang","year":"2005","journal-title":"Int. Immunol."},{"key":"2024091913434023700_bib224","doi-asserted-by":"publisher","first-page":"247426","DOI":"10.1155\/2015\/247426","article-title":"Effect of TACI signaling on humoral immunity and autoimmune diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"J. Immunol. Res."},{"key":"2024091913434023700_bib225","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1007\/s10620-016-4136-z","article-title":"B cell-activating factor as a new potential marker in inflammatory bowel disease","volume":"61","author":"Zhang","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"2024091913434023700_bib226","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/s41401-020-00582-4","article-title":"BAFF, involved in B cell activation through the NF-\u03baB pathway, is related to disease activity and bone destruction in rheumatoid arthritis","volume":"42","author":"Zhang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"2024091913434023700_bib227","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"2024091913434023700_bib228","doi-asserted-by":"publisher","first-page":"1901507","DOI":"10.1183\/13993003.01507-2019","article-title":"Shared genetics of asthma and mental health disorders: a large-scale genome-wide cross-trait analysis","volume":"54","author":"Zhu","year":"2019","journal-title":"Eur Respir J."},{"key":"2024091913434023700_bib229","article-title":"Zura bio announces $80 million financing and the licensing of Tibulizumab (ZB-106), a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for autoimmune diseases. Zura Bio Ltd. (Press release)","author":"Zura Bio Ltd","year":"2023"},{"key":"2024091913434023700_bib230","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jaci.2019.09.035","article-title":"Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank","volume":"145","author":"Zhu","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"2024091913434023700_bib231","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.11487","article-title":"Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction","volume":"50","author":"Zwerina","year":"2004","journal-title":"Arthritis Rheum."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20240806\/1932503\/jem_20240806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20240806\/1932503\/jem_20240806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:43:58Z","timestamp":1726739038000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/221\/11\/e20240806\/276977\/Targeting-TNF-TNFR-superfamilies-in-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":230,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20240806","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"e20240806"}}